MedTrace Logo

First in Human Study in Subjects With Obesity, But Otherwise Healthy

NCT06252220 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2026-04-09

No results posted yet for this study

Summary

This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, but otherwise healthy subjects.

Conditions

Interventions

DRUG

DA-1726

Active

DRUG

Placebo to DA-1726

Placebo

Sponsors & Collaborators

  • NeuroBo Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Robert Homolka, MS · MetaVia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-25
Primary Completion
2026-11-09
Completion
2026-11-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06252220 on ClinicalTrials.gov